ArticleMikrochimica acta2025
A turn-on fluorescent immunosensor for neurodegenerative disease related neurofilament light chain protein.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Progress in Optical Methods for the Detection of Two Core Blood Biomarkers of Alzheimer's Disease: Amyloid-Beta and Tau Proteins.Biosensors · 2026Review
- Ultrasensitive Detection of Neurofilament Light in Plasma Using F(Ab')Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Direct and selective nanosensor for amyloid-β oligomers in serum for Alzheimer's disease diagnosis.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases (NDs) pose significant challenges to both longevity and quality of life, affecting millions worldwide and ranking as a major cause of global morbidity and disability. There is an urgent need for less invasive, cost-effective diagnostic methods that can reliably detect ND-related biomarkers in readily available biofluids such as serum. In response to this need, we have developed an ultra-sensitive assay that utilizes magnetic nanoparticles and a novel, tailor-made turn-on fluorescent probe named F-SPG. This innovative assay enables the detection of neurofilament light chain (NfL) at femtomolar concentrations, with a remarkable detection limit of 24 fM which is at least 18 times more sensitive than the conventional ELISA kits. Our assay's design eliminates the need for traditional secondary antibody in immunoassay, thereby streamlining the diagnostic process. Recoveries exceeding 95% underscore the assay's precision and reliability. It has proven effective in distinguishing Alzheimer's Disease patients from healthy individuals by quantifying serum NfL levels, showcasing its potential as a cost-effective, ultra-sensitive tool for the early screening of neurodegenerative diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.